The pharmaceutical inventory in Philadelphia is at its highest level in recent years, and that could be due to one mass tort program: Risperdal.
According to the First Judicial District’s most recent statistics regarding the mass tort litigation in Philadelphia’s Complex Litigation Center, 5,601 pharmaceutical cases were pending as of Jan. 1. That’s nearly 200 more pharmaceutical cases than were pending at the start of 2012—the year the court began implementing changes aimed at clearing its mass tort inventory.
